MedTrace Logo

A Study of Olomorasib (LY3537982) in Healthy Participants

NCT07439250 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-05-19

No results posted yet for this study

Summary

The main purpose of this study in healthy participants is to determine the effect of fluconazole on the amount of study drug that gets into the bloodstream and how long it takes the body to get rid of it. For each participant, the study will last up to approximately 7 weeks and will require 12 overnight stays in the research center.

Conditions

  • Healthy

Interventions

DRUG

Olomorasib

Administered orally

DRUG

Fluconazole

Administered orally

Sponsors & Collaborators

Principal Investigators

  • Contact Lilly at 1-877-CTLILLY (1-877-285-4559) or · Eli Lilly and Company

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-02
Primary Completion
2026-04-17
Completion
2026-04-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07439250 on ClinicalTrials.gov